Thursday, March 24, 2022 at 11am EDT | 8am PDT | 3pm GMT | 4pm CET Join this webinar to hear industry thought leaders discuss the process and building blocks of end-to-end clinical development, explore the essential elements of a unified clinical platform, and share the benefits and challenges involved in realizing the vision of a unified clinical platform.
Register Free: http://www.pharmexec.com/pe_w/platform
The clinical development technology platform market, including related services, is expected to reach more than $15 billion by 2026. The interest in this market is driven by pharmaceutical companies that are looking to address challenges in the orchestration of the many and complex activities that are a part of the clinical development process. Today, clinical development and IT leaders are turning to a mix of technology platforms offered by various software providers to manage this complexity.
However, given the technological advancements across data, insights, cloud and connectivity, the market may be ready to tackle one of today’s most important questions in the life sciences industry: are market forces finally aligned to deliver a unified clinical platform to support the end-to-end clinical development process? In this webinar, life sciences industry experts will discuss this question and share their perspectives on:
Key Learning Objectives:
Who Should Attend:
Timothy F. Coleman
Vice President and Information Officer, Medicines Development Unit
Eli Lilly and Company
Tim Coleman is currently Vice President and Information Officer, Medicines Development Information & Digital Solutions, at Eli Lilly and Company, where he is responsible for IT strategies and solutions for R&D business areas. In this role, he directs a global portfolio of digital initiatives in partnership with Lilly business and scientific executives. Projects delivered within his portfolio have been recognized nationally for digital innovation and visionary leadership, including the CIO100 Award, FutureEdge 50 Award, and the Bio-IT World Best Practices Award in Clinical Research.
Tim has held several positions in the Lilly Global Information and Digital Solutions organization, supporting US and global sales & marketing, manufacturing, and research & development. In addition, he has held business roles in the human resources and sales & marketing components, including P&L responsibility as District Sales Leader for the Lilly Osteoporosis Specialty Business Unit. Tim earned his Bachelor of Science in Industrial Management and Computer Science from Purdue University and his Master of Management (MBA) from the Kellogg Graduate School of Management at Northwestern University.
Tim is a passionate advocate for STEM youth education and enjoys giving to support his community. He currently serves on the board of directors for the TechPoint Foundation for Youth, the Indianapolis Public Schools Foundation, and as the Executive Champion for BDPA Indianapolis. Tim is also a board member with the Krenicki Center for Business Analytics & Machine Learning at Purdue University. He has previously served on computer science corporate advisory boards for multiple universities.
Avi Kulkarni, Ph.D.
SVP, Head of Life Sciences R&D
Avi Kulkarni leads Cognizant’s Global Life Sciences Research and Development team. He serves biopharma and medical device clients across discovery, clinical development, pharmacovigilance, and regulatory functions. He is responsible for commercial development and planning, and he leads P&L execution across R&D services, partnered products and internal platforms.
Avi has been at the forefront of the drugs and diagnostics industry for over three decades, building new drug formulations, launching new diagnostic tests, publishing extensively in personalized medicine, and building capabilities in cellular therapies. Prior to joining Cognizant in June 2021, he served as Managing Director and Head of Accenture’s global clinical business, where he drove double-digit annual growth.
Before Accenture, Avi was Senior Vice President and Leader of IQVIA, a clinical research organization. Previously, he was Global Head of Life Sciences R&D at Booz & Co., a management consulting company. He also held CXO roles at three biotechnology startups spun out from Stanford University and funded by Sand Hill Road Venture Capital.
Avi holds a master’s degree and a PhD in pharmaceutics from Temple University, as well as an MBA from Stanford University. After graduating from Stanford, Avi remained in the San Francisco Bay Area for nearly three decades, where he currently lives with his wife and daughter.
Sr. Director, Life Sciences and Global Head of R&D Solutions
Venu Mallarapu is Senior Director for Life Sciences and Global Head of R&D Solutions at Cognizant, which helps life sciences organizations around the world to accelerate innovation through end-to-end digital process transformation across pharma and medical device R&D. In his role, he is responsible for taking Cognizant’s R&D service offerings to clients across the globe. He acts as a trusted advisor and strategic partner to address clients’ challenges and realize their vision, goals, and objectives. He also manages multiple strategic partnerships with leading R&D platform vendors. He has over 23 years’ experience in business and IT advisory, strategic consulting, relationship, and delivery management, with 15+ years of experience in life sciences research & development. He is a subject matter expert and thought leader in clinical, regulatory, quality, and safety & pharmacovigilance functions. He has delivered strategy & transformation advisory consulting to top global pharma, biotech, vaccine, and medical devices clients. He has been a speaker at various life sciences and tech industry events and is a recognized thought leader in R&D with published articles. He is also an occasional blogger through his personal “Living on the Edge” blog.
Register Free: http://www.pharmexec.com/pe_w/platform